2. Overview of outcomes.

Outcome	Definition	Unit of outcome measurement	Referred to as/abbreviation	Prioritisation
Complete control of nausea	No nausea and no significant nausea, as defined on a study levela Assessed for: acute phase: first 24 h of treatment with chemotherapy delayed phase: after 24 to 120 h of treatment with chemotherapy overall: 0 to 120 h of treatment with chemotherapy	Binary; participants with complete control of nausea	No nausea	Overall phase prioritised for GRADE assessment
Complete control of vomiting	No vomiting and no use of rescue medications Assessed for: acute phase: first 24 h of treatment with chemotherapy delayed phase: after 24 to 120 h of treatment with chemotherapy overall: 0 to 120 h of treatment with chemotherapy	Binary; participants with complete control of vomiting	Complete response (CR)	Delayed and overall phases prioritised for GRADE assessment Overall phase chosen as most important efficacy outcome
Quality of life	No impairment in quality of life during active study period	Binary; participants with no impairment in quality of life	QoL	Prioritised for GRADE assessment
On‐study mortality	Deaths occurring from randomisation up to 30 days after the active study period	Binary; participants who died	OSM	Prioritised for GRADE assessment
Adverse events	As defined on a study level; during active study period	Binary; participants with at least 1 event	AEs	‐
Serious adverse events	As defined on a study level; during active study period	Binary; participants with at least 1 event	SAEs	Prioritised for GRADE assessment  Chosen as most crucial safety outcome
Neutropenia	As defined on a study level; during active study period	Binary; participants with at least 1 event	‐	‐
Febrile neutropenia	As defined on a study level; during active study period	Binary; participants with at least 1 event	‐	‐
Infection	As defined on a study level; during active study period	Binary; participants with at least 1 event	‐	‐
Local reaction at infusion site	As defined on a study level; during active study period	Binary; participants with at least 1 event	‐	Prioritised for GRADE assessment
Hiccup	As defined on a study level; during active study period	Binary; participants with at least 1 event	‐	‐

^aStandardised tools are typically used to assess degree of nausea and vomiting (Wood 2011). No nausea and no significant nausea were defined on a study level and typically refer to pre‐defined cutoffs, e.g. in Rapoport 2015 (a) or Schwartzberg 2015, nausea was assessed on a visual analogue scale (VAS; 0 to 100 mm; 0 = no nausea, 100 = severe nausea; < 5 mm = no nausea, < 25 mm = no significant nausea). No significant nausea is typically more subjective because of the wider range on the scale and is therefore less objective, especially in an open‐label study design. To increase comparability of studies and minimise biased results, we were therefore interested in patients with no nausea.